½ÃÀ庸°í¼­
»óÇ°ÄÚµå
1403413

´õ¸» ÇÊ·¯ ½ÃÀå ¿¹Ãø(-2030³â) : Á¦Ç°, ¾à¹° À¯Çü, Àç·á, À¯Åë ä³Î, ¿ëµµ, ÃÖÁ¾ »ç¿ëÀÚ ¹× Áö¿ªº° ¼¼°è ºÐ¼®

Dermal Fillers Market Forecasts to 2030 - Global Analysis By Product (Biodegradable, Non-Biodegradable and Other Products), Drug Type, Material, Distribution Channel, Application, End User and By Geography

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Stratistics Market Research Consulting | ÆäÀÌÁö Á¤º¸: ¿µ¹® 200+ Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    



¡Ø º» »óÇ°Àº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

Stratistics MRC¿¡ µû¸£¸é ´õ¸» ÇÊ·¯ ¼¼°è ½ÃÀåÀº 2023³â 55¾ï ´Þ·¯·Î ÃßÁ¤µÇ¸ç, ¿¹Ãø ±â°£ µ¿¾È ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR) 9.8%·Î ¼ºÀåÇÏ¿© 2030³â 105¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

´õ¸» ÇÊ·¯´Â Á© ÇüÅÂÀÇ Àç·á¸¦ »ç¿ëÇÏ´Â Àúħ½ÀÀû Ä¡·á¹ýÀÔ´Ï´Ù. À̵éÀº ¾ó±¼ ÇǺÎÀÇ ¿Ü°üÀ» °³¼±ÇÏ´Â µ¥ »ç¿ëµÇ¸ç ÁÖ»çÁ¦ ÇüÅ·ΠÁ¦°øµË´Ï´Ù. ÀÌ·¯ÇÑ Ä¡·á´Â ÁÖ¸§À» ÃÖ¼ÒÈ­ÇÏ¿© ´õ Àþ¾î º¸ÀÌ°Ô ÇÏ´Â µ¥ ±â¿©ÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ½Ã¼úÀº ¿©µå¸§ ÈäÅ͸¦ ÁÙÀÌ°í ÀÔ¼ú°ú ¾ó±¼ÀÇ ÁÖ¸§À» °³¼±ÇÏ´Â µ¥ µµ¿òÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù.

¼¼°èº¸°Ç±â±¸(WHO)ÀÇ Ã߻꿡 µû¸£¸é 2030³â±îÁö Àü ¼¼°è Àα¸ 6¸í Áß 1¸íÀÌ 60¼¼ ÀÌ»óÀÌ µÉ °ÍÀ̶ó°í ÇÕ´Ï´Ù. Åë°è¿¡ µû¸£¸é ³ëÀÎ Àα¸´Â 2020³â 10¾ï ¸í¿¡¼­ 2050³â 21¾ï ¸íÀ¸·Î µÎ ¹è·Î ´Ã¾î³¯ °ÍÀÔ´Ï´Ù.

¼ºÀå ÃËÁø¿äÀÎ: ÃÖ¼Òħ½À¼ö¼ú Áõ°¡

Àúħ½ÀÀû ¼ö¼ú·Î ¾Ë·ÁÁø ÀÌ Ä¡·á´Â Ư¼öÇÑ ¼ö¼ú ±â±¸¿Í ½Ã¾ß¸¦ È®º¸ÇÒ ¼ö ÀÖ´Â ½ºÄÚÇÁ¸¦ »ç¿ëÇÏ¿© ½ÃÇàµË´Ï´Ù. ÀÜÁÖ¸§À̳ª ÀÜÁÖ¸§°ú °°Àº ¾ó±¼ÀÇ ÀÌ»ó¿¡ ÃÊÁ¡À» ¸ÂÃß¾î °úµµÇÑ Áö¹æ, ºÎÇÇ ¹× À±°ûÀ» ÁÙÀÔ´Ï´Ù. Àúħ½ÀÀû ¿¡³ÊÁö ±â¹Ý ÇǺΠ°­È­, ÁÖ¸§ °¨¼Ò, ¾ó±¼ Á¶°¢, ÇǺΠȸÃá ½Ã¼ú¿¡ ´ëÇÑ ¼ö¿ä´Â Àü ¼¼°èÀûÀ¸·Î Å®´Ï´Ù. µû¶ó¼­ ÃÖ¼Ò Ä§½ÀÀû ½Ã¼úÀÇ º¸±ÞÀÌ Áõ°¡ÇÏ¸é ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¼ºÀå ¾ïÁ¦¿äÀÎ: ´õ¸» ÇÊ·¯¿¡ µû¸¥ ºÎÀÛ¿ë

¿µ±¸ÀûÀÎ ´õ¸» ÇÊ·¯¸¦ ¸¸µå´Â µ¥ »ç¿ëµÇ´Â ¼ººÐÀº ÀÎü°¡ ¼ÒÈ­ÇÒ ¼ö ¾ø½À´Ï´Ù. ±× °á°ú, ½Åü´Â ¾Æ¸¶µµ Àڱ⠹æ¾î¸¦ÇÒ °ÍÀÌ°í, °¨¿°°ú »ý¹°¸·ÀÇ ¹ß»ýÀ» Æ÷ÇÔÇÑ °á°ú¸¦ ÃÊ·¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¿µ±¸ ÇÊ·¯´Â ÀÎü¿¡ µ¹ÀÌų ¼ö ¾ø´Â Çظ¦ ³¢Ä¡°í Á¦°ÅµÇÁö ¾Ê½À´Ï´Ù. ´õ¸» ÇÊ·¯ »ç¿ëÀ¸·Î ÀÎÇÑ ºÎÀÛ¿ë¿¡ ´ëÇÑ »ç¶÷µéÀÇ ¿ì·Á°¡ Ä¿Áö¸é¼­ ½ÃÀåÀÇ ÁøÈ­¸¦ ¾î´À Á¤µµ Á¦ÇÑÇÒ ¼ö ÀÖ½À´Ï´Ù.

±âȸ: »õ·Î¿î ´õ¸» ÇÊ·¯ÀÇ ¹ßÀü

´õ¸» ÇÊ·¯´Â Á©°ú À¯»çÇÑ È­ÇÕ¹°·Î, ÁÖ¸§À» ºÎµå·´°Ô ÇÏ°í ÁÖ¸§À» ¿ÏÈ­ÇÏ°í ÀÒ¾î¹ö¸° º¼·ýÀ» º¸ÃæÇϱâ À§ÇØ ÇǺΠ¾Æ·¡¿¡ ÁÖÀԵ˴ϴÙ. ¼ö¼úÀ̳ª ´Ù¿îŸÀÓÀÌ ÇÊ¿ä ¾ø´Â ÀÌ ÇÊ·¯´Â Àþ¾î º¸ÀÌ°Ô ÇÏ´Â À¯¿ëÇÑ Ä¡·á ¿É¼ÇÀÔ´Ï´Ù. ÀÌ ¾à¹°Àº ÇǺΠ¾Æ·¡¿¡ ÁÖÀÔµÇ¾î ¾ó±¼ÀÇ ÁÖ¸§À» Æì±â À§ÇØ ÇǺΠ¾Æ·¡¿¡ ÁÖÀԵ˴ϴÙ. È÷¾Ë·ç·Ð»ê°ú Ä®½· ÇÏÀ̵å·Ï½Ã¾ÆÆÄŸÀÌÆ® µîÀÌ À¯¸íÇÕ´Ï´Ù. ´õ¸» ÇÊ·¯ ºê·£µåÀÇ °³¼±ÀÌ ½ÃÀå ¼ö¿ä Áõ°¡¿¡ ±â¿©ÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

À§Çù: ¹Ì¿ë ½Ã¼úÀÇ ³ôÀº ºñ¿ë

ºñ¿ëÀº ¼±ÅÃÀû ½Ã¼úÀ» ÇÒ ¶§ °í·ÁÇØ¾ß ÇÒ ¿ä¼ÒÀÔ´Ï´Ù. ´õ¸» ÇÊ·¯ÀÇ ºñ¿ëÀº ½Ã¼ú¿¡ »ç¿ëµÇ´Â ÇÊ·¯ÀÇ À¯Çü°ú ¾ç¿¡ µû¶ó ´Þ¶óÁý´Ï´Ù. ½Ã¼ú ºñ¿ëÀº ¶ÇÇÑ ´õ¸» ÇÊ·¯¸¦ ½Ã¼úÇÏ´Â ½Ã¼úÀÚÀÇ ÈƷðú °æÇè¿¡ µû¶ó ´Þ¶óÁý´Ï´Ù. ´õ¸» ÇÊ·¯´Â ÀÒ¾î¹ö¸° º¼·ýÀ» ȸº¹ÇÏ°í ´Ù¾çÇÑ ³ëÈ­ ¡Èĸ¦ Ä¡·áÇÒ ¼ö ÀÖ´Â Àαâ ÀÖ´Â ¹Ì¿ë ¼ºÇüÀÔ´Ï´Ù. ¾ÈÀüÇÑ ¿Ü·¡ ¼ö¼úÀÌÁö¸¸ Ä¡·á ºñ¿ëÀÌ ºñ½Î±â ¶§¹®¿¡ ½ÃÀå ¼ö¿ä´Â Á¦ÇÑÀûÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

COVID-19ÀÇ ¿µÇâ

Äڷγª19ÀÇ ´ëÀ¯ÇàÀº ¹Ì¿ë ÇǺΰú ¹× ¹Ì¿ë ÀÇ·á »ê¾÷¿¡ ºÎÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÃÆÀ¸¸ç, ±¹Á¦ÀûÀ¸·Î »ý»ê ¹®Á¦¿Í °ø±Þ¸Á Áß´ÜÀ» °Þ¾ú½À´Ï´Ù. ºÀ¼â Á¶Ä¡, ¿©Çà Á¦ÇÑ, ³ëµ¿·Â °¨¼Ò´Â ¸ðµÎ ´õ¸» ÇÊ·¯ÀÇ »ý»ê, À¯Åë ¹× ¿î¼Û Áö¿¬À¸·Î À̾îÁ® ¿©·¯ Áö¿ª¿¡¼­ Á¦Ç° ºÎÁ· ¹× °¡¿ë¼º Á¦ÇÑÀ» ÃÊ·¡Çß½À´Ï´Ù. ¶ÇÇÑ, Àü¿°º´ÀÌ ÀýÁ¤¿¡ À̸£·¶À» ¶§ ¹Ì¿ë ½Ã¼úÀ» Æ÷ÇÔÇÑ ¼±ÅÃÀû ÀÇ·á ÀýÂ÷°¡ ¾ö°ÝÇÏ°Ô Á¦ÇѵǾú½À´Ï´Ù. ÀÌ·Î ÀÎÇØ ÇÊ¿äÇÏÁö ¾ÊÀº Áø·á¼Ò´Â ÀϽÃÀûÀ¸·Î Æó¼âµÇ¾î ¹Ì¿ë ¼­ºñ½º¿¡ ´ëÇÑ ¼ö¿ä°¡ ±Þ°ÝÈ÷ °¨¼ÒÇß½À´Ï´Ù.

¿¹Ãø ±â°£ µ¿¾È »ýºÐÇؼº ºÎ¹®ÀÌ °¡Àå Å« ºñÁßÀ» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»ó

¿¹Ãø ±â°£ µ¿¾È »ýºÐÇؼº ºÎ¹®ÀÌ °¡Àå Å« ºñÁßÀ» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ Á¦Ç°µéÀº ¾ó±¼ÀÇ Æ¯Â¡À» ¸ð¹æÇϸ鼭 ºÎµå·´°í ÀÚ¿¬½º·¯¿î ¿ÜÇüÀû Áõ°¡¸¦ ¸¸µé¾î³»´Â °ÍÀ» ¸ñÇ¥·Î ÇÕ´Ï´Ù. ÀÔ¼úÀ̳ª »´°ú °°Àº ¾ó±¼ÀÇ Æ¯Â¡À» °³¼±ÇÏ°í, ÁÖ¸§°ú ÀÜÁÖ¸§À» ä¿ì°í, ¾ó±¼¿¡ º¼·ýÀ» ´õÇÏ´Â µ¥ »ç¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. »ýºÐÇؼº ´õ¸» ÇÊ·¯´Â ¿µ±¸ÀûÀÎ ÇÊ·¯¿Í ´Þ¸® ½Ã°£ÀÌ Áö³²¿¡ µû¶ó ¼­¼­È÷ ºÐÇصǾî ü³»¿¡ Èí¼öµÇ´Â °ÍÀ» ¸ñÇ¥·Î ÇÕ´Ï´Ù. À̴ ȯÀÚ°¡ º¯È­ÇÏ´Â ¿ä±¸¿Í ÃëÇâ¿¡ µû¶ó ¿Ü¸ð¸¦ ¼öÁ¤ÇÒ ¼ö ÀÖ´Ù´Â °ÍÀ» ÀǹÌÇÕ´Ï´Ù.

¿¹Ãø ±â°£ µ¿¾È È÷¾Ë·ç·Ð»ê ºÎ¹®Àº °¡Àå ³ôÀº CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

È÷¾Ë·ç·Ð»ê ºÎ¹®Àº ¿¹Ãø ±â°£ µ¿¾È °¡Àå ³ôÀº CAGRÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ±íÀº ÁÖ¸§, ÀÜÁÖ¸§, º¼·ý °¨¼Ò´Â È÷¾Ë·ç·Ð»ê ´õ¸» ÇÊ·¯·Î ÇØ°áÇÒ ¼ö ÀÖ´Â ¹®Á¦ Áß ÀϺο¡ ºÒ°úÇÕ´Ï´Ù. ¶ÇÇÑ ÈäÅÍ ¹× ±âŸ ÇǺΠ°áÇÔÀÇ ¿Ü°üÀ» °³¼±ÇÏ°í ÀÔ¼ú°ú ±¤´ë»À¸¦ °­Á¶ÇÏ´Â µ¥ »ç¿ëµÇ±âµµ ÇÕ´Ï´Ù. È÷¾Ë·ç·Ð»ê ÇÊ·¯´Â ´Ù¾çÇÑ Á¦ÇüÀ¸·Î Á¦°øµÇ±â ¶§¹®¿¡ ½Ã¼úÀÚ´Â °¢ ȯÀÚÀÇ Æ¯Á¤ ¿ä±¸ »çÇ׿¡ ¸Â´Â Ä¡·á¸¦ ÇÒ ¼ö ÀÖ½À´Ï´Ù.

°¡Àå Å« Á¡À¯À²À» Â÷ÁöÇÏ´Â Áö¿ª

¿¹Ãø ±â°£ µ¿¾È ºÏ¹Ì°¡ °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ´Â ³²¼ºÀÇ Àαâ Áõ°¡, ³ëÈ­ ¹æÁö ºäƼ Æ®·»µå, ºñ¼ö¼úÀû ¼ºÇü ¼ö¼ú¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡ µîÀ¸·Î ÀÎÇÑ °ÍÀ¸·Î ºÐ¼®µË´Ï´Ù. ÀÌ Áö¿ª ÁֹεéÀº ¾Æ¸§´Ù¿ò°ú À°Ã¼Àû ¸Å·Â¿¡ ´ëÇÑ ÀÌ»óÀ» °­ÇÏ°Ô ÀνÄÇÏ°í ÀÖ½À´Ï´Ù. ÀÌ¿¡ µû¶ó ¾ó±¼ÀÇ Æ¯Â¡À» °³¼±ÇÏ°í ³ëÈ­ Áõ»óÀ» ¿ÏÈ­ÇÏ´Â ¹æ¹ýÀ¸·Î ´õ¸» ÇÊ·¯¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÏ°í ÀÖ½À´Ï´Ù.

CAGRÀÌ °¡Àå ³ôÀº Áö¿ª

¾Æ½Ã¾ÆÅÂÆò¾çÀº ¿¹Ãø ±â°£ µ¿¾È °¡Àå ³ôÀº CAGRÀ» À¯ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ Áö¿ª¿¡¼­´Â °¡Ã³ºÐ ¼ÒµæÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ¹Ì¿ë ¼ºÇü ¼ö¼úÀ» ¹ÞÀ» ¼ö ÀÖ´Â »ç¶÷µéÀÌ ´Ã¾î³¯ ¼ö ÀÖ½À´Ï´Ù. ÀÌ Áö¿ªÀº ÀÇ·á °ü±¤Áö·Î ÀαⰡ ³ô¾Æ ¸¹Àº »ç¶÷µéÀÌ ¼ºÇü¼ö¼úÀ» ¹Þ±â À§ÇØ ÀÌ Áö¿ªÀ» ¹æ¹®ÇÏ°í ÀÖÀ¸¸ç, ÀÌ Áö¿ªÀÇ »ê¾÷Àº ºü¸£°Ô ¼ºÀåÇÏ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀÌ Áö¿ªÀÇ ¾Æ¸§´Ù¿ò¿¡ ´ëÇÑ ÀÌ»óÀº ÁøÈ­ÇÏ°í ÀÖÀ¸¸ç, Å« ÀÔ¼ú°ú ³ôÀº ±¤´ë»À¿Í °°Àº Ư¡¿¡ Á¡Á¡ ´õ ¸¹Àº °ü½ÉÀ» ±â¿ïÀÌ°í ÀÖ½À´Ï´Ù.

¹«·á ¸ÂÃãÇü ¼­ºñ½º

ÀÌ º¸°í¼­¸¦ ±¸µ¶ÇÏ´Â °í°´Àº ´ÙÀ½°ú °°Àº ¹«·á ¸ÂÃãÈ­ ¿É¼Ç Áß Çϳª¸¦ ÀÌ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù.

  • ±â¾÷ ÇÁ·ÎÆÄÀÏ
    • Ãß°¡ ½ÃÀå ±â¾÷ Á¾ÇÕ ÇÁ·ÎÆÄÀϸµ(ÃÖ´ë 3°³»ç±îÁö)
    • ÁÖ¿ä ±â¾÷ÀÇ SWOT ºÐ¼®(3°³»ç±îÁö)
  • Áö¿ª ¼¼ºÐÈ­
    • °í°´ÀÇ °ü½É¿¡ µû¸¥ ÁÖ¿ä ±¹°¡º° ½ÃÀå ÃßÁ¤ ¹× ¿¹Ãø, CAGR(Âü°í: Ÿ´ç¼º È®Àο¡ µû¶ó ´Ù¸§)
  • °æÀï»ç º¥Ä¡¸¶Å·
    • Á¦Ç° Æ÷Æ®Æú¸®¿À, Áö¸®Àû ÀÔÁö, Àü·«Àû Á¦ÈÞ¸¦ ±â¹ÝÀ¸·Î ÇÑ ÁÖ¿ä ±â¾÷ º¥Ä¡¸¶Å·

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ¼­¹®

  • °³¿ä
  • ÀÌÇØ°ü°èÀÚ
  • Á¶»ç ¹üÀ§
  • Á¶»ç ¹æ¹ý
    • µ¥ÀÌÅÍ ¸¶ÀÌ´×
    • µ¥ÀÌÅÍ ºÐ¼®
    • µ¥ÀÌÅÍ °ËÁõ
    • Á¶»ç Á¢±Ù
  • Á¶»ç ¼Ò½º
    • 1Â÷ Á¶»ç ¼Ò½º
    • 2Â÷ Á¶»ç ¼Ò½º
    • ÀüÁ¦Á¶°Ç

Á¦3Àå ½ÃÀå µ¿Ç⠺м®

  • ¼ºÀå ÃËÁø¿äÀÎ
  • ¼ºÀå ¾ïÁ¦¿äÀÎ
  • ±âȸ
  • À§Çù
  • Á¦Ç° ºÐ¼®
  • ¿ëµµ ºÐ¼®
  • ½ÅÈï ½ÃÀå
  • ½ÅÇü Äڷγª¹ÙÀÌ·¯½º(COVID-19)ÀÇ ¿µÇâ

Á¦4Àå PorterÀÇ Five Forces ºÐ¼®

  • °ø±Þ ±â¾÷ÀÇ ±³¼··Â
  • ¹ÙÀ̾îÀÇ ±³¼··Â
  • ´ëüǰÀÇ À§Çù
  • ½Å±Ô ÁøÃâ¾÷üÀÇ À§Çù
  • ±â¾÷°£ °æÀï °ü°è

Á¦5Àå ¼¼°èÀÇ ´õ¸» ÇÊ·¯ ½ÃÀå : Á¦Ç°º°

  • »ýºÐÇؼº
    • ¹Ý¿µ±¸Àû
    • ÀϽÃÀû
  • ºñ»ýºÐÇؼº
  • ±âŸ Á¦Ç°

Á¦6Àå ¼¼°èÀÇ ´õ¸» ÇÊ·¯ ½ÃÀå : ¾àÁ¦ À¯Çüº°

  • Á¦³×¸¯
  • ºê·£µå

Á¦7Àå ¼¼°èÀÇ ´õ¸» ÇÊ·¯ ½ÃÀå : Àç·áº°

  • Poly-L-lactic Acid
  • Ä®½· ÇÏÀ̵å·Ï½Ç ¾ÆÆÄŸÀÌÆ®
  • Áö¹æ ÇÊ·¯
  • È÷¾Ë·ç·Ð»ê
  • ±âŸ Àç·á

Á¦8Àå ¼¼°èÀÇ ´õ¸» ÇÊ·¯ ½ÃÀå : À¯Åë ä³Îº°

  • ¼Ò¸Å ¾à±¹
  • ¿Â¶óÀÎ ¾à±¹
  • Á÷Á¢ ÀÔÂû
  • µå·°½ºÅä¾î
  • ±âŸ À¯Åë ä³Î

Á¦9Àå ¼¼°èÀÇ ´õ¸» ÇÊ·¯ ½ÃÀå : ¿ëµµº°

  • ¾ó±¼ ±³Á¤
  • ÁÖ¸§ °³¼±
  • ¼Õ ȸÃá
  • À½°æ È®´ë
  • ¿©µå¸§ ÈäÅÍ
  • Áö¹æ À§Ãà
  • ÀÔ¼ú °­È­
  • °í°üÀý Áõ°­
  • À¯¹æ È®´ë
  • ¾È°Ë ¼ºÇü¼ú
  • ¸ñ ¹× ÅÎ ¸®ÇÁÆ®
  • ¾ó±¼ ¸®ÇÁÆ®
  • ±âŸ ¿ëµµ

Á¦10Àå ¼¼°èÀÇ ´õ¸» ÇÊ·¯ ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°

  • ÇǺΰú Ŭ¸®´Ð
  • º´¿ø
  • ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC)
  • Çмú¿¬±¸±â°ü
  • ±âŸ ÃÖÁ¾»ç¿ëÀÚ

Á¦11Àå ¼¼°èÀÇ ´õ¸» ÇÊ·¯ ½ÃÀå : Áö¿ªº°

  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
    • ¸ß½ÃÄÚ
  • À¯·´
    • µ¶ÀÏ
    • ¿µ±¹
    • ÀÌÅ»¸®¾Æ
    • ÇÁ¶û½º
    • ½ºÆäÀÎ
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • ÀϺ»
    • Áß±¹
    • Àεµ
    • È£ÁÖ
    • ´ºÁú·£µå
    • Çѱ¹
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ³²¹Ì
    • ¾Æ¸£ÇîƼ³ª
    • ºê¶óÁú
    • Ä¥·¹
    • ±âŸ ³²¹Ì
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
    • īŸ¸£
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦12Àå ÁÖ¿ä ¹ßÀü

  • °è¾à/ÆÄÆ®³Ê½Ê/Çù¾÷/ÇÕÀÛÅõÀÚ(JV)
  • Àμö ¹× ÇÕº´
  • ½ÅÁ¦Ç° ¹ß¸Å
  • »ç¾÷ È®´ë
  • ±âŸ ÁÖ¿ä Àü·«

Á¦13Àå ±â¾÷ °³¿ä

  • Allergan
  • Anika Therapeutics, Inc.
  • BIOXIS Pharmaceuticals
  • Elan aesthetics Inc
  • FillMed Laboratories
  • Galderma Laboratories, L.P.
  • Merz Pharma
  • Prollenium Medical Technologies
  • Teoxane Laboratories
  • Revance Therapeutics, Inc.
  • Sinclair Pharma
  • Suneva Medical
  • Vital Esthetique Laboratories
  • Contura International ltd.
  • Zimmer Aesthetic
  • BioPlus Co., Ltd.
LSH 24.01.19

According to Stratistics MRC, the Global Dermal Fillers Market is accounted for $5.5 billion in 2023 and is expected to reach $10.5 billion by 2030 growing at a CAGR of 9.8% during the forecast period. Dermal fillers are less invasive treatments that employ gel-based materials. These are utilized to enhance the appearance of the facial skin and come in the form of injectables. These treatments contribute to a more youthful appearance by minimizing wrinkles. These procedures are helpful in reducing acne scars and are utilized to improve lips and facial wrinkles.

According to WHO estimates, by 2030, one in every six people in the world will be 60 or older. As per statistics, the geriatric population size will get double from 1 billion in 2020 to 2.1 billion in 2050.

Market Dynamics:

Driver:

Rising prevalence of minimally-invasive procedures

A treatment known as minimally-invasive surgery is one that is carried out with the use of specialized surgical tools and a scope for seeing. It reduces extra fat, volume, and contour while focusing on face abnormalities including fine lines and wrinkles. There is a great demand worldwide for minimally invasive energy-based skin tightening, wrinkle reduction, face sculpting, and skin rejuvenation procedures. Thus, the increasing prevalence of minimally invasive procedures is expected to drive growth in the market.

Restraint:

Side effects associated with dermal fillers

The ingredients used to make permanent dermal fillers are indigestible to the human body. As a result, the body will probably defend itself, which might result in consequences including infections and the development of biofilms. Furthermore, permanent fillers harm the human body irreversibly and are not removed. A rising number of people's concerns about the negative consequences of using dermal fillers may limit the market's evolution to some extent.

Opportunity:

Advancement in the new dermal fillers

Dermal fillers are compounds that resemble gel and are injected beneath the skin to smooth lines, soften wrinkles, and replenish lost volume. Without requiring surgery or downtime, these fillers are a useful therapeutic option for looking younger. This medication is injected beneath the skin to help plump up wrinkles on the face. This medications come in a variety of forms; the most popular ones are hyaluronic acid and calcium hydroxylapatite, among others. Improvements in dermal filler brands will contribute to increased market demand.

Threat:

High cost of aesthetic procedures

Cost is a factor that is taken into account for elective procedures. Dermal filler costs vary based on the kind and quantity utilized in the procedure. The cost of the procedure also depends on the training and experience of the practitioner applying dermal fillers. Dermal filler is a popular cosmetic operation that may restore lost volume and cure various indications of aging. It is a safe outpatient procedure, but the expensive cost of the treatments is anticipated to limit market demand.

COVID-19 Impact:

The COVID-19 pandemic had a detrimental influence on the cosmetic dermatology and aesthetic medicine industries, which suffered production issues and supply chain interruptions internationally. Lockdown procedures, travel restrictions, and a smaller labor force all contributed to delays in dermal filler manufacture, distribution, and transit, which in turn resulted in shortages and restricted availability in different areas. Furthermore, at the pandemic's height, there were severe restrictions on elective medical procedures, including beauty treatments. This led to the temporary closure of non-essential clinics and a sharp drop in the demand for cosmetic services.

The biodegradable segment is expected to be the largest during the forecast period

The biodegradable segment is expected to be the largest during the forecast period. They are intended to create a mild, natural-looking augmentation while imitating the facial features. They can be used to improve facial features like the lips and cheeks, fill in wrinkles and fine lines, and add volume to the face. Biodegradable dermal fillers, in contrast to permanent fillers, are intended to progressively degrade and be absorbed by the body over time. This implies that patients can modify their look to suit their changing demands and tastes.

The hyaluronic acid segment is expected to have the highest CAGR during the forecast period

The hyaluronic acid segment is expected to have the highest CAGR during the forecast period. Deep creases, wrinkles, fine lines, and volume loss are just a few of the issues that can be resolved with hyaluronic acid dermal fillers. They may also be used to improve the look of scars and other skin defects, as well as to accentuate the lips and cheekbones. Because they come in various formulations, practitioners may tailor therapies to the specific requirements of each patient.

Region with largest share:

North America is projected to hold the largest market share during the forecast period. This is due to males are becoming more popular, there is a growing trend of ageless beauty in the area, and there is an increased need for non-surgical cosmetic operations. The region's populace is very conscious of ideals of beauty and physical attractiveness. Because of this, dermal fillers are in high demand as a way to improve face characteristics and lessen aging symptoms.

Region with highest CAGR:

Asia Pacific is projected to hold the highest CAGR over the forecast period. More people in the area may afford cosmetic operations as disposable income rises. Due to the region's popularity as a medical tourism destination, many individuals come here for cosmetic procedures-the area industry has grown rapidly. In addition, the region's ideals of beauty are evolving, placing an increasing focus on characteristics like big lips and high cheekbones.

Key players in the market:

Some of the key players in Dermal Fillers market include Allergan , Anika Therapeutics, Inc., BIOXIS Pharmaceuticals, Elan aesthetics Inc, FillMed Laboratories, Galderma Laboratories, L.P., Merz Pharma, Prollenium Medical Technologies, Teoxane Laboratories, Revance Therapeutics, Inc., Sinclair Pharma, Suneva Medical, Vital Esthetique Laboratories, Contura International ltd., Zimmer Aesthetic and BioPlus Co., Ltd.

Key Developments:

In April 2023, Sinclair Pharma announced that it has received European CE mark for Perfectha Lidocaine, a hyaluronic acid dermal filler pre-mixed with lidocaine. This will make the filler more comfortable for patients to receive.

In March 2023, Revance Therapeutics announced that it has submitted a new drug application (NDA) to the US Food and Drug Administration (FDA) for TAO, a hyaluronic acid dermal filler for the correction of moderate to severe facial wrinkles and folds.

In February 2023, Galderma received FDA approval for Restylane Defyne, a hyaluronic acid dermal filler for chin augmentation. This is the first FDA-approved dermal filler specifically for chin augmentation.

Products Covered:

  • Biodegradable
  • Non-Biodegradable
  • Other Products

Drug Types Covered:

  • Generic
  • Branded

Materials Covered:

  • Poly-L-lactic Acid
  • Calcium hydroxyl apatite
  • Fat Fillers
  • Hyaluronic acid
  • Other Materials

Distribution Channels Covered:

  • Retail Pharmacy
  • Online Pharmacy
  • Direct Tender
  • Drug Stores
  • Other Distribution Channels

Applications Covered:

  • Facial Corrections
  • Wrinkles Reduction
  • Hand Rejuvenation
  • Penis Enlargement
  • Acne Scar
  • Lipoatrophy
  • Lip Enhancement
  • Hip Augmentation
  • Breast Enhancement
  • Blepharoplasty
  • Neck & Chin lift
  • Face Lift
  • Other Applications

End Users Covered:

  • Dermatology Clinics
  • Hospitals
  • Ambulatory Surgical Centers
  • Academic Research Institutes
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Application Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Dermal Fillers Market, By Product

  • 5.1 Introduction
  • 5.2 Biodegradable
    • 5.2.1 Semi-Permanent
    • 5.2.2 Temporary
  • 5.3 Non-Biodegradable
  • 5.4 Other Products

6 Global Dermal Fillers Market, By Drug Type

  • 6.1 Introduction
  • 6.2 Generic
  • 6.3 Branded

7 Global Dermal Fillers Market, By Material

  • 7.1 Introduction
  • 7.2 Poly-L-lactic Acid
  • 7.3 Calcium hydroxyl apatite
  • 7.4 Fat Fillers
  • 7.5 Hyaluronic acid
  • 7.6 Other Materials

8 Global Dermal Fillers Market, By Distribution Channel

  • 8.1 Introduction
  • 8.2 Retail Pharmacy
  • 8.3 Online Pharmacy
  • 8.4 Direct Tender
  • 8.5 Drug Stores
  • 8.6 Other Distribution Channels

9 Global Dermal Fillers Market, By Application

  • 9.1 Introduction
  • 9.2 Facial Corrections
  • 9.3 Wrinkles Reduction
  • 9.4 Hand Rejuvenation
  • 9.5 Penis Enlargement
  • 9.6 Acne Scar
  • 9.7 Lipoatrophy
  • 9.8 Lip Enhancement
  • 9.9 Hip Augmentation
  • 9.10 Breast Enhancement
  • 9.11 Blepharoplasty
  • 9.12 Neck & Chin lift
  • 9.13 Face Lift
  • 9.14 Other Applications

10 Global Dermal Fillers Market, By End User

  • 10.1 Introduction
  • 10.2 Dermatology Clinics
  • 10.3 Hospitals
  • 10.4 Ambulatory Surgical Centers
  • 10.5 Academic Research Institutes
  • 10.6 Other End Users

11 Global Dermal Fillers Market, By Geography

  • 11.1 Introduction
  • 11.2 North America
    • 11.2.1 US
    • 11.2.2 Canada
    • 11.2.3 Mexico
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 UK
    • 11.3.3 Italy
    • 11.3.4 France
    • 11.3.5 Spain
    • 11.3.6 Rest of Europe
  • 11.4 Asia Pacific
    • 11.4.1 Japan
    • 11.4.2 China
    • 11.4.3 India
    • 11.4.4 Australia
    • 11.4.5 New Zealand
    • 11.4.6 South Korea
    • 11.4.7 Rest of Asia Pacific
  • 11.5 South America
    • 11.5.1 Argentina
    • 11.5.2 Brazil
    • 11.5.3 Chile
    • 11.5.4 Rest of South America
  • 11.6 Middle East & Africa
    • 11.6.1 Saudi Arabia
    • 11.6.2 UAE
    • 11.6.3 Qatar
    • 11.6.4 South Africa
    • 11.6.5 Rest of Middle East & Africa

12 Key Developments

  • 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 12.2 Acquisitions & Mergers
  • 12.3 New Product Launch
  • 12.4 Expansions
  • 12.5 Other Key Strategies

13 Company Profiling

  • 13.1 Allergan
  • 13.2 Anika Therapeutics, Inc.
  • 13.3 BIOXIS Pharmaceuticals
  • 13.4 Elan aesthetics Inc
  • 13.5 FillMed Laboratories
  • 13.6 Galderma Laboratories, L.P.
  • 13.7 Merz Pharma
  • 13.8 Prollenium Medical Technologies
  • 13.9 Teoxane Laboratories
  • 13.10 Revance Therapeutics, Inc.
  • 13.11 Sinclair Pharma
  • 13.12 Suneva Medical
  • 13.13 Vital Esthetique Laboratories
  • 13.14 Contura International ltd.
  • 13.15 Zimmer Aesthetic
  • 13.16 BioPlus Co., Ltd.
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óÇ°À» ¼±Åà Áß
»óÇ° ºñ±³Çϱâ
Àüü»èÁ¦